Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 17/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20817800 | 0.88 | TRPC5 (1.00) | TRPC5KDM4ALMNAHSD17B10 | |
| SCHEMBL20818353 | 0.88 | TRPC5 (1.00) | TRPC5KDM4ALMNAHSD17B10 | |
| SCHEMBL20831374 | 0.87 | TRPC5 (0.60) | TRPC5ALDH1A1TIPARPKCNH2TRPC4 | |
| SCHEMBL20831868 | 0.87 | TRPC5 (0.60) | TRPC5ALDH1A1TIPARPKCNH2TRPC4 | |
| SCHEMBL20831652 | 0.86 | TRPC5 (0.59) | TRPC5ALDH1A1KCNH2TRPC4 | |
| SCHEMBL20831651 | 0.86 | TRPC5 (0.59) | TRPC5ALDH1A1TIPARPTRPC4 | |
| SCHEMBL20831648 | 0.86 | TRPC5 (0.59) | TRPC5ALDH1A1TIPARPTRPC4 | |
| SCHEMBL20818574 | 0.84 | TRPC5 (0.67) | TRPC5TIPARPKCNH2TRPC4 | |
| SCHEMBL20818117 | 0.84 | TRPC5 (0.67) | TRPC5TIPARPKCNH2TRPC4 | |
| SCHEMBL20831687 | 0.83 | TRPC5 (0.55) | TRPC5ALDH1A1TIPARPKCNH2TRPC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885ALDH1A1 649/4885TIPARP 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.